Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday, August 1st.
Several other brokerages have also commented on ATRA. Canaccord Genuity reaffirmed a “buy” rating and issued a $47.00 price objective on shares of Atara Biotherapeutics in a research report on Friday, April 21st. Jefferies Group LLC reiterated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Finally, William Blair reiterated an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, June 26th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Atara Biotherapeutics has a consensus rating of “Hold” and a consensus target price of $25.75.
Atara Biotherapeutics (ATRA) traded down 2.20% during midday trading on Tuesday, reaching $13.35. 176,322 shares of the company traded hands. The company has a 50 day moving average of $14.97 and a 200-day moving average of $15.91. Atara Biotherapeutics has a 12-month low of $11.80 and a 12-month high of $23.40. The stock’s market capitalization is $407.96 million.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by $0.05. Equities analysts anticipate that Atara Biotherapeutics will post ($3.96) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Atara Biotherapeutics, Inc. (ATRA) Lowered to “Strong Sell” at ValuEngine” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.com-unik.info/2017/08/19/atara-biotherapeutics-inc-atra-rating-lowered-to-strong-sell-at-valuengine-updated-updated.html.
In related news, CEO Isaac E. Ciechanover sold 2,800 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $16.94, for a total transaction of $47,432.00. Following the completion of the transaction, the chief executive officer now owns 731,859 shares of the company’s stock, valued at $12,397,691.46. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Mitchall G. Clark sold 3,021 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $14.33, for a total transaction of $43,290.93. The disclosure for this sale can be found here. Insiders sold 52,059 shares of company stock valued at $752,211 in the last quarter. Corporate insiders own 16.10% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Atara Biotherapeutics during the first quarter valued at approximately $132,000. Voya Investment Management LLC boosted its position in shares of Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 1,651 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Atara Biotherapeutics during the first quarter valued at approximately $185,000. State of Wisconsin Investment Board purchased a new position in shares of Atara Biotherapeutics during the second quarter valued at approximately $252,000. Finally, The Manufacturers Life Insurance Company boosted its position in Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after buying an additional 1,369 shares in the last quarter. 78.21% of the stock is owned by institutional investors.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Atara Biotherapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Atara Biotherapeutics Inc. and related companies.